The Neuroprotective Effects of Oxaloacetate in Closed Head Injury in Rats is Mediated by its Blood Glutamate Scavenging Activity
Authors:
- Shaun E. GruenbaumSGShaun E. Gruenbaum
- Alan A. ArtruAAAlan A. Artru
- Irene RozetIRIrene Rozet
- Michael DubiletMDMichael Dubilet
- Sergey TkachovSTSergey Tkachov
- Evgeny BrotfainEBEvgeny Brotfain
- Yael KlinYKYael Klin
- Yoram ShapiraYSYoram Shapira
- Vivian I. TeichbergVTVivian I. Teichberg
- 1 July 2009
- journal article
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 21 (3) , 235-241
Abstract
Treatment with oxaloacetate after traumatic brain injury has been shown to decrease blood glutamate levels and protect against the neurotoxic effects of glutamate on the brain. A number of potential mechanisms have been suggested to explain oxaloacetate-induced neuroprotection. We hypothesize that the primary mechanism by which intravenous oxaloacetate provides neuroprotection is by activation of the blood glutamate-scavenging enzyme glutamate-oxaloacetate transaminase, increasing thereby the driving force for the efflux of excess glutamate from brain interstitial fluids into blood. If so, coadministration of maleate, a glutamate-oxaloacetate transaminase-blocker is expected to prevent the neuroprotective effects of oxaloacetate. A neurological severity score (NSS) was measured 1 hour after closed head injury (CHI) in rats. Then, rats received 30 microL/min/100 g infusion of saline, or 1 mmol/100 g solution of oxaloacetate, maleate, or a mixture of oxaloacetate and maleate. NSS was reassessed at 24 and 48 hour after CHI. Blood glutamate and glucose levels were measured at 0, 60, 90, and 120 minutes. NSS improved significantly at 24 hour (P<0.001) and 48 hour (P<0.001) only in the rats treated with oxaloacetate. Blood glutamate decreased significantly in the oxaloacetate-treated group at 90 minute (at the conclusion of oxaloacetate administration) (P<0.00001), but not in the control, maleate or oxaloacetate+maleate groups. A strong correlation r2=0.86 was found to exist between the percent decrease in blood glutamate levels and percent improvement in NSS. The results of this study demonstrate that the primary mechanism by which oxaloacetate provides neuroprotective activity after CHI is related to its blood glutamate scavenging activity. Management of blood glutamate concentration may have important implications in the treatment of acute brain conditions, including CHI and stroke.Keywords
This publication has 36 references indexed in Scilit:
- Homeostasis of glutamate in brain fluids: An accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologiesNeuroscience, 2009
- Blood‐mediated scavenging of cerebrospinal fluid glutamateJournal of Neurochemistry, 2003
- Molecular signatures of brain injury after intracerebral hemorrhageNeurology, 2002
- Glutamate uptakeProgress in Neurobiology, 2001
- The Developing Nervous System: A Series of Review Articles: Neurobiology of Hypoxic-Ischemic Injury in the Developing BrainPediatric Research, 2001
- Molecular Mechanisms of Glutamate Receptor-Mediated Excitotoxic Neuronal Cell DeathMolecular Neurobiology, 2001
- Na+-dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain BarrierJournal of Biological Chemistry, 1999
- Progression of ischaemic stroke and excitotoxic aminoacidsThe Lancet, 1997
- Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic StrokeStroke, 1996
- AMINO ACID AND PROTEIN METABOLISM‐VI CEREBRAL COMPARTMENTS OF GLUTAMIC ACID METABOLISMJournal of Neurochemistry, 1961